ARCHIVES

Lilly drug Alimta misses the target, but wins ODAC endorsement for lung cancer. FDA’s Pazdur tells ODAC that decision on Alimta requires clinical judgment.

This article is from The Cancer Letter archive.

Vol. 30 No. 31 | July 30, 2004

Download PDF Visit The Full Archive

Related Articles

FDA approves Irinotecan, Days After ODAC Meeting

June 21, 1996

New CREG Cell Kinetics Study Axed By DCTBSC

March 31, 1978

The Lancet Oncology Retracts Potti Paper, NEJM Doesn’t

February 4, 2011

In Brief: House Bill Boosts NIH Funding By $1.2 Billion; ASCO Counted More Than 17,000 Registrants

June 26, 1998

In Brief: BRI Gets New FCRF Basic Research Contract; Senate Subcommittee Less Generous Than House

October 2, 1987

FDA News: ODAC Clears Photofrin For Microinvasive NSCLC

September 26, 1997